Therapeutic efficacy and safety of carbetocin on postpartum hemorrhage

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015613

Enrollment

Unknown

Registered

2018-04-11

Start date

2018-04-10

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum hemorrhage

Interventions

Research group:Carbetin oxytocin intravenous injection

Control group:oxytocin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) planned cesarean delivery full-term mothers; 2) at least one of the following risk factors: scar uterus, uterine fibroids, breech, giant, early primipara (age = 35 years).

Exclusion criteria

Exclusion criteria: 1) Multiple pregnancy; 2) placenta previa; 3) suspicious placenta accreta; 4) combined with systemic diseases (liver and kidney dysfunction, heart disease or hypertension need treatment, endocrine disease, except gestational diabetes); 5) coagulation dysfunction; 6) hypersensitivity to carbetocin.

Design outcomes

Primary

Measure	Time frame
The amount of postpartum hemorrhage;	—

Countries

China

Contacts

Public ContactYun Wang

Suzhou Municipal Hospital

13776035935@126.com+86 0512-62362082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026